StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
PALIBullishEarningsnews
High materiality8/10

Palisade Bio advances PALI-2108 to Phase 2 with strong balance sheet

Aug 10, 2026, 4:30 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Clear near-term catalysts (IND clearances, 2H 2026 trial starts, 2H 2027/2028 readouts) plus a solid cash runway and management execution tone could re-rate a clinically de-risked, late-stage pipeline vs peers; however, execution risk remains until readouts materialize.

AI summary

What happened, with direct paths to the underlying reporting

Palisade Bio advances PALI-2108 into Phase 2 for UC and CD after FDA IND clearance and solid Phase 1 signals. The UC readout is slated for 2H 2027, with CD readout targeted in early 2028, while cash resources of $125.2 million support milestones. New board additions may help execution and fundraising ahead of pivotal readouts.

  • Phase 2 ASCENTRA-UC to start 2H 2026; ASCENTRA-CD IND planned 2H 2026.
  • IND clearance received; UC readout expected 2H 2027; CD IND filed 2H 2026.
  • IND for ASCENTRA-CD planned 2H 2026; CD trial start 1Q 2027; readout 2028.
  • Phase 1 UC results show strong responses; FSCD SES-CD down 47.5%.
  • Cash $125.2M supports milestones; board adds Baltera and Zwick.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event